This is a ready-to-use PPQ summary report. It is the document an inspector reads most closely, because it states the conclusion: is the process validated or not. Replace every <<FILL: ...>> placeholder with your own specifics, present actual values rather than “pass,” and route it through document control. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it. This is general guidance to adapt, not legal or regulatory advice.
Approval page
| Field | Entry |
|---|---|
| Report title | PPQ Summary Report for <<FILL: PRODUCT, STRENGTH, PRESENTATION>> |
| Report number | <<FILL: RPT-ID, e.g. VAL-PPQ-023-RPT>> |
| Version | <<FILL>> |
| Executed under protocol | <<FILL: protocol number and version>> |
| Site | <<FILL>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Validation / PV lead) | <<FILL>> | ||
| Process / Manufacturing SME | <<FILL>> | ||
| Analytical / QC | <<FILL>> | ||
| Quality Assurance (approver) | <<FILL>> |
1. Purpose and reference to protocol
This report presents the results of the PPQ executed under protocol <<FILL: protocol number>> for <<FILL: PRODUCT>>, and states whether the commercial process is qualified. Execution followed the approved protocol except where documented in section 5.
2. Executed batches and variability spanned
| Batch | Manufacturing date | Equipment | Operator / shift | Critical material lot(s) | Yield |
|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
Confirm that the batch set spanned the variability sources committed to in the protocol’s number-of-batches rationale: <<FILL: material lots, operators, shifts, equipment trains represented>>.
3. Results against acceptance criteria
Present actual values with the margin to the limit, not just “pass.” A reviewer wants to see the numbers.
| Attribute / parameter | Acceptance criterion | Batch 1 | Batch 2 | Batch 3 | Verdict |
|---|---|---|---|---|---|
<<FILL: assay>> | <<FILL>> | <<FILL: actual>> | <<FILL>> | <<FILL>> | <<FILL: pass/fail>> |
<<FILL: content uniformity>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL: blend uniformity (mean, RSD)>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL: dissolution>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL: CPP within PAR>> | Within proven acceptable range | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
4. Statistical analysis
Report the analysis pre-registered in the protocol: descriptive statistics, trend or control charts, and preliminary capability with the sample-size caveat.
| Attribute | Mean (across batches) | Variability (SD / RSD) | Trend | Preliminary capability | Note |
|---|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL: none / describe>> | <<FILL: indicative only>> | Full Cpk deferred to CPV |
A small number of PPQ batches does not support a reliable Cpk. Capability shown here is preliminary and indicative; formal capability is established in CPV once enough lots accumulate.
5. Departures from the protocol
| Departure | Description | Justification | Impact on conclusion |
|---|---|---|---|
<<FILL: none, or list>> | <<FILL>> | <<FILL>> | <<FILL>> |
6. Deviations and OOS results
Every deviation and OOS that occurred during execution is listed with its investigation outcome and impact on the PPQ conclusion. Omitting a deviation that occurred is a serious integrity finding.
| Reference | Description | Root cause | CQA impact | Impact on PPQ conclusion |
|---|---|---|---|---|
<<FILL: DEV/OOS number or "none">> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
7. Discussion of results near or outside limits
<<FILL: any result near a limit, with the scientific rationale, or "all results comfortably within limits with margin recorded in section 3">>.
8. Conclusion
<<FILL: The commercial process for [PRODUCT] IS / IS NOT qualified.>> All acceptance criteria in the protocol were <<FILL: met / partially met with justification>>. <<FILL: conditions or follow-ups, e.g. items carried into CPV>>.
9. Continued process verification (CPV) bridge
The parameters and attributes Stage 3 will monitor, the control limits, and the review cadence. This makes the qualified state something that is verified going forward, not asserted once.
| Monitored parameter / attribute | Control limit / alert-action | Monitoring frequency | Review cadence |
|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL: each batch / weekly>> | <<FILL: quarterly / per APR>> |
Enhanced monitoring carried forward (e.g. resin lifetime, infrequent material lots, hold-time effects): <<FILL: list or "none">>.
10. References
FDA Guidance for Industry, Process Validation: General Principles and Practices (January 2011). 21 CFR 211.192 (production record review), 211.100, 211.110. EudraLex Volume 4, Annex 15: Qualification and Validation (2015). ICH Q9(R1), Q10; ICH Q13 for continuous manufacturing where applicable.
Confirm the current version of each reference before issue.
11. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen (excerpt)
Illustrative results-against-criteria excerpt for the immediate-release tablet used in the PPQ protocol specimen. Numbers are illustrative; replace them with your own.
| Attribute | Acceptance criterion | Batch 1 | Batch 2 | Batch 3 | Verdict |
|---|---|---|---|---|---|
| Assay | 95.0-105.0% | 99.6% | 100.2% | 99.1% | Pass |
| Content uniformity (AV) | Meets USP <905>; AV <= 15.0 | 4.1 | 5.3 | 4.7 | Pass |
| Blend uniformity | Mean 95-105%, RSD <= 5.0% | mean 100.1%, RSD 2.1% | mean 99.4%, RSD 2.8% | mean 100.6%, RSD 2.3% | Pass |
| Dissolution (Q at 30 min) | Q >= 80% | 96% | 94% | 97% | Pass |
| Blending time (CPP) | 12-18 min | 15 min | 15 min | 16 min | Pass |
Deviation excerpt: DEV-2026-0217 (batch 2): a single tablet-press feed-frame stall, assignable to a transient over-fill, corrected within the run; assessed as isolated with no content-uniformity or assay impact (batch 2 results in range). Impact on PPQ conclusion: none. Conclusion: the commercial process is qualified; capability to be established in CPV; three parameters (assay, content-uniformity AV, dissolution) carried into the CPV plan with control limits.
The point the specimen makes: the report shows the actual numbers and their margin, names the one deviation openly with its impact, and does not overclaim capability from three lots. That is what “inspection-ready” looks like.
Common inspection findings this report prevents
- The report says “pass” everywhere but shows no actual values or margin to the limit.
- A deviation that occurred during execution is missing from the report.
- A precise Cpk is claimed as established capability from three lots.
- The conclusion asserts qualification but there is no CPV bridge, so Stage 3 is empty.
- Departures from the protocol are silently absorbed rather than documented and justified.
How to adapt this report
- Reference the exact protocol number and version the batches were run under.
- Fill the batch table so a reader can see the variability the batch set spanned.
- Present actual values in section 3, not verdict words alone.
- List every deviation and OOS with its impact; never omit one.
- State the conclusion plainly and make the CPV bridge concrete (parameters, limits, cadence).
- Confirm every regulation in section 10 against the current published version before issue.